Crohn’s disease sufferers treated with Stelara (ustekinumab) experienced clinical response and clinical remission, according to phase III data from maker, a Johnson & Johnson Janssen (NYSE: JNJ) subsidiary.
The trial featured adult patients with moderate to severe Crohn's who had previously failed or were intolerant to one or more anti-tumour necrosis factor (TNF)-alpha therapies.
The data, presented at the 11th Congress of the European Crohn's and Colitis Organisation (ECCO), is important because there are relatively few treatment options available for patients who did not respond to TNF inhibitors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze